Neurofibromatosis Type 1 Pipeline Analysis Report 2026

Report Coverage

The Neurofibromatosis Type 1 Pipeline Analysis Report by Expert Market Research gives comprehensive insights into neurofibromatosis type 1 therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for neurofibromatosis type 1. The neurofibromatosis type 1 report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The neurofibromatosis type 1 pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with neurofibromatosis type 1 treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to neurofibromatosis type 1.

Read more about this report - Request a Free Sample

Neurofibromatosis Type 1 Pipeline Outlook

Neurofibromatosis type 1 (NF1) is a genetic disorder caused by mutations in the NF1 gene, leading to abnormal nerve tissue growth. It presents with café-au-lait spots, neurofibromas, learning disabilities, and skeletal deformities. The condition arises from inherited or spontaneous mutations affecting the tumor suppressor protein neurofibromin, resulting in uncontrolled cell proliferation.

Neurofibromatosis type 1 treatments aim to manage symptoms, limit tumor growth, and enhance quality of life. Approaches include surgical tumor removal, targeted therapies such as kinase inhibitors, and supportive care for pain, skin, and neurological issues. In February 2025, mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) received FDA approval for adult and pediatric patients aged two years and older with symptomatic plexiform neurofibromas not amenable to complete resection, showing confirmed overall response rates of 41% in adults and 52% in pediatric patients, representing a notable advancement in NF1 therapy.

Neurofibromatosis Type 1 Epidemiology

The pipeline is gaining attention due to the disorder’s clinical complexity and tumor predisposition. According to Minhua Liao et al., 2025, NF1 is an autosomal-dominant genetic disorder caused by pathogenic variants in the NF1 gene, affecting approximately 1 in 3000 individuals globally. As per Rare Disease Advisor, NF1 is classified as a rare disease in both the United States and the European Union. As per Elisa Moya Kazmarek et al., 2024, the United Kingdom reports a prevalence of 1 in 4560 and an incidence of 1 in 2699, with nearly 50% of cases inherited. Said Farschtschi et al., 2025, report an incidence of approximately 1 in 3000 newborns in Germany.

Neurofibromatosis Type 1 – Pipeline Therapeutic Assessment

Neurofibromatosis Type 1 Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total neurofibromatosis type 1 clinical trials. Phase II leads with 53%, driven by advanced efficacy studies and expanding patient enrollment. Phase I holds 37%, supported by safety assessments and early biomarker evaluations. Phase III contributes 8%, reflecting pivotal trials and regulatory progress. This distribution underscores strong research momentum and potential market growth.

Neurofibromatosis Type 1 Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the neurofibromatosis type 1 pipeline analysis include small molecules, monoclonal antibodies, and peptides. The neurofibromatosis type 1 report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for neurofibromatosis type 1. MEK inhibitors are emerging as a key therapeutic class in the neurofibromatosis type 1 drug pipeline. For example, Koselugo (selumetinib), an oral selective MEK inhibitor, is approved in the US for adults with symptomatic, inoperable plexiform neurofibromas. It works by inhibiting the MAPK/ERK pathway, reducing tumour growth and associated pain, disfigurement, and functional impairment in NF1 patients.

Neurofibromatosis Type 1 Clinical Trials – Key Players

The EMR report for the neurofibromatosis type 1 pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed neurofibromatosis type 1 therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in neurofibromatosis type 1 clinical trials:

• Healx Limited
• Shanghai Kechow Pharma, Inc.
• Pasithea Therapeutics Corp.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Novotech (Australia) Pty Limited
• AstraZeneca
• Merck Sharp & Dohme LLC
• SpringWorks Therapeutics, Inc.
• PRG Science & Technology Co., Ltd.
• Novartis Pharmaceuticals

Neurofibromatosis Type 1 – Emerging Drugs Profile

Key Questions Answered in the Neurofibromatosis Type 1 Pipeline Insight Report

• Which companies/institutions are leading the neurofibromatosis type 1 drug development?
• Which company is leading the neurofibromatosis type 1 pipeline development activities?
• What is the current neurofibromatosis type 1 commercial assessment?
• What are the opportunities and challenges present in the neurofibromatosis type 1 pipeline landscape?
• What is the efficacy and safety profile of neurofibromatosis type 1 pipeline drugs?
• Which company is conducting major trials for neurofibromatosis type 1 drugs?
• Which companies/institutions are involved in neurofibromatosis type 1 collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in neurofibromatosis type 1?

Reasons To Buy This Report

The Neurofibromatosis Type 1 Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for neurofibromatosis type 1. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into neurofibromatosis type 1 collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Glioma Market

Glioma Epidemiology Forecast